Abstract
Trastuzumab (Herceptin®) is a humanized monoclonal antibody that binds selectively to human epidermal growth factor 2 (HER2), interfering with its downstream cancer-promoting effects. This article focuses on the efficacy and tolerability of trastuzumab in HER2-positive advanced gastric cancer. The potential of trastuzumab as a cytotoxic for use in gastric cancer was confirmed by in vitro studies in HER2-positive gastric cancer cell lines and gastric cancer xenograft models. In a randomized, controlled, open-label, multinational trial in patients with HER2-positive advanced gastric cancer, trastuzumab plus chemotherapy (cisplatin plus capecitabine or 5-fluorouracil) was significantly more efficacious than chemotherapy alone, in terms of a longer median overall survival (13.8 vs. 11.1 months in the chemotherapy alone group) [primary endpoint], a longer median progression-free survival, and a higher response rate. Trastuzumab was efficacious across patient subgroups, although stronger effects were observed in a subgroup with high HER2 overexpression (immunohistochemistry 2+/fluorescence in-situ hybridization positive or immunohistochemistry 3+). There was a slightly higher tolerability burden in the trastuzumab plus chemotherapy group than with chemotherapy alone, based on small between-group numerical differences in rates of common gastrointestinal and general adverse events. Most individual adverse events reported in this trial were at a grade 1 or 2 level of severity. However, in both treatment groups approximately half of the haematological adverse were at a grade 3 or 4 level of severity, with no marked between-group differences. Trastuzumab in combination with cisplatin and a fluoropyrimidine is an effective regimen for patients with HER2-positive advanced gastric cancer, has acceptable tolerability and represents an important advance in the treatment of gastric cancer.
Similar content being viewed by others
References
Delanoit T. Latest developments and emerging treatment options in the management of stomach cancer. Cancer Manag Res. 2011;3(1):257–66.
Bang YJ. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer. J Clin Gastroenterol. 2012;46(8):637–48.
Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–50.
Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer. 2012;3:137–44.
Janjigian YY, Werner D, Pauligh C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23(10):2656–62.
European Medicines Agency. Herceptin 150 mg powder for concentrate for solution for infusion: summary of product characteristics. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf. Accessed 7 August 2013.
Genentech, Inc. Herceptin® (trastuzumab): US prescribing Information 2010. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf. Accessed 7 August 2013.
Chugai Pharmaceutical Co., Ltd. Anti-cancer agent, Herceptin® obtained approval for additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection [media release]. 10 March 2011. http://www.chugai-pharm.co.jp.
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39–51.
Croxtall JD, McKeage K. Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs. 2010;70(17):2259–67.
Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008;32(1):89–95.
Fujimoto-Ouchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59(6):795–805.
Yamade M, Sugimoto M, Nishino M, et al. Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence. Anticancer Res. 2012;32(1):105–14.
Li X-L, Yi S-Q, Xu J-M, et al. The sequence-dependent cytotoxic effect of trastuzumab in combination with 5-fluorouracil or cisplatin on gastric cancer cell lines. Cancer Invest. 2010;28(10):1038–47.
Yoshida R, Tazawa H, Hashimoto Y, et al. Mechanism of resistance to trastuzumab and molecular sensitization via ADCC activation by exogenous expression of HER2-extracellular domain in human gastric cancer cells. Cancer Immunol Immunother. 2012;612:1905–16.
Wainberg ZA, Anghel A, Rogers AM, et al. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 2013;12(4):509–19.
Shi M, Yang Z, Hu M, et al. Catecholamine-induced beta2-adrenergic receptor activation mediates desensitization of gastric cancer cells to trastuzumab by upregulating MUC4 expression. J Immunol. 2013;190(11):5600–8.
Satoh T, Omuro Y, Sasaki Y, et al. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer. Cancer Chemother Pharmacol. 2012;69(4):949–55.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
Sawaki A, Ohashi Y, Omuro Y, et al. Efficacy of trastuzumab in Japanese patients with HER2-positive advanced gastric or gastroesophageal junction cancer: a subgroup analysis of the Trastuzumab for Gastric Cancer (ToGA) study. Gastric Cancer. 2012;15(3):313–22.
Satoh T, Leon J, Lopez RI, et al. Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer [abstract no. 7]. American Society of Clinical Oncology: Gastrointestinal Cancers Symposium; 22-24 January 2010; Chicago, IL, USA.
Ohtsu A, Wang L, Lim H, et al. Quality of life results from a phase III study of trastuzumab plus chemotherapy as first-line therapy in patients with HER2-positive advanced gastric and gastro-esophageal junction cancer [abstract O-0011]. Ann Oncol. 2010; 21 Suppl.:vi14.
Kang YK, Shen L, Lichinitser M, et al. Self-rated pain assessment by patients with HER2-positive advanced gastric/GEJ cancer treated with 5-FU/capecitabine and cisplatin with or without trastuzumab: exploratory QOL analysis from the phase III ToGA study [abstract Sa1016]. Gastroenterology. 2011;140(5 Suppl. 1):S204.
Chung HC, Bang Y, Van Cutsem E, et al. (Q)-TWiST analysis of trastuzumab plus fluoropyrimidine/cisplatin (T-XP/FP) versus XP/FP alone as first-line therapy for advanced HER2-positive gastric cancer [abstract no. 4048]. J Clin Oncol. 2010; 28(15 Suppl.).
Okines A, Verheij M, Allum W, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v50–4.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: gastric cancer (version 2.2013). http://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf. Accessed 7 August 2013.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver 3). Gastric Cancer. 2011. doi:10.1007/s10120-011-0042-4.
Sano T, Aiko T. New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points. Japanese Gastric Cancer Association. Gastric Cancer. 2011;14:97–100.
Gencer D, Al-Batran SE, Dada R, et al. Metastatic esophagogastric adenocarcinoma: trends in first-line treatment and predictive factors for implementation of HER2 testing in clinical practice during the first year after trastuzumab market approval. J Cancer Res Clin Oncol. 2013;139(2):337–45.
Norman G, Rice S, Spackman E, et al. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction. Health Technol Assess (Winchester, England). 2011;15(Suppl 1):33–42.
Holden J, Garrett Z, Stevens A. NICE guidance on trastuzumab for the treatment of HER2-positive metastatic gastric cancer. Lancet Oncol. 2011;12(1):16–7.
Wu B, Ye M, Chen H, et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther. 2012;34(2):468–79.
Hoffmann-La Roche, Ltd. A study of Perjeta (pertuzumab) in combination with Herceptin (trastuzumab) and chemotherapy in patients with HER2-positive metastatic gastroesophageal junction or gastric cancer. http://clinicaltrials.gov/ct2/show/NCT01774786. Accessed 28 May 2013.
Hoffmann-La Roche, Ltd. A study of trastuzumab emtansine versus taxane in patients with advanced gastric cancer. http://clinicaltrials.gov/ct2/show/NCT01641939. Accessed 28 May 2013.
Hoffmann-La Roche, Ltd. HELOISE Study: a study of Herceptin (trastuzumab) in combination with cisplatin/capecitabine chemotherapy in patients with HER2-positive metastatic gastric or gastro-esophageal junction cancer. http://clinicaltrials.gov/ct2/show/NCT01450696. Accessed 28 May 2013.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from any comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: A. Anthoney, Medical Oncology, CRUK Clinical Cancer Centre, Bexley Wing, St James Hospital, Leeds, UK; W. Eisterer, Department of Internal Medicine, Innsbruck Medical University, Innsbruck, Austria.
Rights and permissions
About this article
Cite this article
Sanford, M. Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer. Drugs 73, 1605–1615 (2013). https://doi.org/10.1007/s40265-013-0119-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-013-0119-y